Neurocrine Biosciences Stock News

Neurocrine Biosciences (NASDAQ:NBIX) had its price target upped by equities research analysts at Oppenheimer from $140.00 to $154.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Oppenheimers price objective indicates a potential upside of 88.68% from the companys current price. Oppenheimer []

Neurocrine Biosciences (NASDAQ:NBIX)s stock had its buy rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday, Analyst Price Targets reports. They presently have a $139.00 price target on the stock. HC Wainwrights target price suggests a potential upside of 70.30% from the stocks current price. Other equities research []

Zacks Investment Research upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports. According to Zacks, Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The companys []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin

Neurocrine Biosciences Inc (NASDAQ: NBIX ) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with Huntington''s disease (HD). The selective vesicular monoamine transporter 2 (VMAT2) inhibitor is being investigated as a once-daily treatment in adult patients. Chorea is a movement disorder that causes involuntary, irregular, unpredictable muscle movements. The study met the primary endpoint of reduction in the severity of chorea, the cardinal Full story available on Benzinga.com

Neurocrine Biosciences Inc (NASDAQ: NBIX) revealed topline data from its Phase 3 KINECT-HD study evaluating Ingrezza (valbenazine) for chorea associated with Huntington's disease (HD).  The select

SAN DIEGO, Dec. 7, 2021 /PRNewswire/ -- Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line data from its Phase 3

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)s share price hit a new 52-week low on Monday following insider selling activity. The stock traded as low as $78.31 and last traded at $80.11, with a volume of 957 shares traded. The stock had previously closed at $80.64. Specifically, Director Gary A. Lyons sold 5,000 shares of the businesss stock [] The post Neurocrine Biosciences (NASDAQ:NBIX) Reaches New 52-Week Low Following Insider Selling appeared first on ETF Daily News .

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy sold 1,645 shares of the stock in a transaction on Wednesday, December 1st. The stock was sold at an average price of $82.59, for a total value of $135,860.55. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. NBIX []

Wall Street brokerages expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will post $319.79 million in sales for the current quarter, according to Zacks. Eleven analysts have made estimates for Neurocrine Biosciences earnings. The lowest sales estimate is $310.39 million and the highest is $347.10 million. Neurocrine Biosciences reported sales of $247.90 million during the same quarter []

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) hit a new 52-week low on Tuesday . The company traded as low as $83.66 and last traded at $84.29, with a volume of 5735 shares trading hands. The stock had previously closed at $84.74. NBIX has been the subject of a number of recent analyst reports. Royal Bank of Canada []

Neurocrine Biosciences, Inc. (NBIX) shares closed today at 0.3% above its 52 week low of $84.50, giving the company a market cap of $8B. The stock is currently down 9.3% year-to-date, down 9.0% over the past 12 months, and up 76.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.9%, and the S&P 500 fell 2.1%. Trading Activity Trading volume this week was 41.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -220.1% The company's stock price performance over the past 12 months lags the peer average by -152.1% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -14.7% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

DNB Asset Management AS reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 14.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 118,279 shares of the companys stock after selling 19,944 shares during the quarter. DNB Asset Management AS []

Neurocrine Biosciences (NASDAQ:NBIX) and Sutro Biopharma (NASDAQ:STRO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, risk, institutional ownership, profitability and valuation. Volatility and Risk Neurocrine Biosciences has a beta of 0.7, indicating that its stock price is […]